Northwestern Cancer Prevention Consortium

西北癌症预防联盟

• 批准号: 10006889
• 负责人: SEEMA Ahsan KHAN
• 金额: $ 197.5万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-03 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10006889
• 关键词: Advisory Committees; Area; Biological; Biological Markers; Breast; Cancer Center Support Grant; Cancer Prevention Trial; Cancer Science; Cities; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Colon; Colon Carcinoma; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Consultations; Development; Disease; Dose; Drug Delivery Systems; Ensure; Evaluation; Fostering; Fright; Fruit; Genetic Predisposition to Disease; Goals; Incidence; Individual; Institution; Intervention; Investigation; Knowledge; Lead; Leadership; Lesion; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Mentors; Methods; Monitor; Mutation; Organ; Pancreas; Pathology; Pathway interactions; Patients; Pharmaceutical Preparations; Physicians; Population; Prevention; Prevention Research; Process; Reproducibility; Research; Research Infrastructure; Research Personnel; Resources; Science; Scientist; Site; Sum; Technology; Testing; Toxic effect; Transdermal substance administration; Universities; Ursidae Family; Work; base; biomarker selection; cancer chemoprevention; cancer prevention; cancer therapy; cancer type; design; early phase clinical trial; early phase trial; improved; innovation; malignant breast neoplasm; malignant oropharynx neoplasm; member; nanoarchitecture; novel; novel marker; predictive marker; programs; protocol development; recruit; reduce symptoms; success; targeted agent; trial design

Northwestern University proposes to continue to lead a consortium of organizations, the Northwestern Cancer Prevention Consortium (NCPC), to design and conduct early phase clinical trials aimed at developing new options for the prevention of cancer. To date, NCPC trials, 19 in total, have accrued 534 patients (354 from the 2003 consortium and 175 from the 2012 consortium), targeting multiple organ sites and a variety of agents. We have tested innovative concepts, e.g., transdermal drug delivery, and utilized novel biomarkers, such as nanocytological alterations. Our proposal to renew the NCPC, under the leadership of Seema A. Khan MD includes academic partners included in the current consortium and new members who are expected to add important strengths to it (the University of Toronto and City of Hope). In the new cycle of the NCPC, we will continue to build on promising approaches based on prior or ongoing successful trials, while providing oversight, consultation, and administrative support to cancer prevention research teams. We will assist in the design of cancer prevention trials, in proposal and protocol development, and in the implementation of such trials. Our overarching goal is to continue our contributions to cancer prevention science through the development of innovative, transformative, early phase trials testing new conceptual approaches that will enable clinical advances in the prevention of cancer. Our Aims are to 1. Advance high priorities in cancer prevention, for maximum impact on cancer incidence when these are advanced into clinical use. These priorities include (i) investigate novel agents and repurposed agents that target mutations and pathways known to be important in the development of cancer, (ii) novel or established biomarkers to identify individuals most like to predict benefit from a given approach, (iii) trials that will result in unifying biological themes across different organ sites, leading to protection against more than one cancer type, (iv) test innovative dosing and delivery methods, to reduce the symptom and toxicity burden for users of cancer prevention agents. 2. Provide consultation, scientific guidance, and mentoring to consortium investigators who are proposing new trial concepts; assist consortium investigators through trial design, initiation, conduct, and analysis; and to serve as the administrative hub of the consortium. We will foster communication, collaboration, and sharing of available resources between consortium members and across consortia, to maximize impact of clinical trials testing similar interventions or in similar populations. Serve as a liaison between the consortium and the NCI DCP, by maintaining and improving an NCPC 3. Advance the science of cancer prevention, through evaluation and selection of innovative or transformative concepts that result in progress that is greater than the sum of knowledge gained from the specific goals of an individual trial. We will be guided in this process by an Advisory Committee with a diverse background in cancer prevention research.

西北大学提议继续领导一个组织联盟——西北癌症协会 预防联盟（NCPC），设计和进行早期临床试验，旨在开发新的 预防癌症的选择。迄今为止，NCPC 试验共有 19 项，已招募了 534 名患者（其中 354 名来自 2003 年的联盟和 2012 年联盟的 175 个），针对多个器官部位和多种药物。我们 测试了创新概念，例如透皮给药，并利用了新颖的生物标志物，例如 纳米细胞学改变。我们提议在 Seema A. Khan 医学博士的领导下更新 NCPC 包括当前联盟中的学术合作伙伴以及预计添加的新成员 它的重要优势（多伦多大学和希望之城）。在新一轮全国人大会议上，我们将 继续以基于先前或正在进行的成功试验的有希望的方法为基础，同时提供 对癌症预防研究团队的监督、咨询和行政支持。我们将协助 癌症预防试验的设计、提案和方案的制定以及此类试验的实施 试验。我们的首要目标是继续为癌症预防科学做出贡献 通过开发创新、变革性的早期试验来测试新概念 这些方法将推动癌症预防的临床进展。我们的目标是 1. 推进癌症预防的高度优先事项，以最大程度地影响癌症发病率 已进入临床使用。这些优先事项包括 (i) 研究新型药物和重新调整用途的药物 已知在癌症发展中重要的目标突变和途径，（ii）新的或 建立生物标志物来识别最喜欢预测特定方法获益的个体，(iii) 试验 这将导致不同器官部位的生物主题统一，从而防止更多的 超过一种癌症类型，(iv) 测试创新的剂量和给药方法，以减轻症状和 癌症预防剂使用者的毒性负担。 2、提供咨询、科学指导、 为提出新试验概念的联盟研究人员提供指导；协助财团调查人员 通过试验设计、启动、实施和分析；并作为行政中心 财团。我们将促进沟通、协作和共享可用资源 联盟成员之间和联盟之间，以最大限度地提高临床试验测试类似的影响 干预措施或类似人群。担任联盟和 NCI DCP 之间的联络人，由 维持和改进 NCPC 3. 通过评估推进癌症预防科学 以及选择创新或变革性概念，从而取得大于总和的进步 从个别试验的具体目标中获得的知识。我们将在此过程中得到指导 由具有癌症预防研究多元化背景的咨询委员会负责。